Key result
High-dose epoprostenol reduces vascular resistance and improves ventricular function in dogs with chronic PH.
Why the study?
Pulmonary hypertension is a life-threatening complication in dogs with cardiopulmonary disease, but the efficacy of the intravenous pulmonary vasodilator epoprostenol remains unknown in dogs.
Do epoprostenol and other intravenous cardiac drugs improve cardiovascular hemodynamics in canine models of chronic pulmonary hypertension?
Do epoprostenol and other intravenous cardiac drugs improve cardiovascular hemodynamics in canine models of chronic pulmonary hypertension?
In a canine model of chronic pulmonary hypertension, epoprostenol and pimobendan improved ventricular function without worsening pulmonary pressures, whereas catecholamines (dobutamine and dopamine) increased pulmonary arterial pressure.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for high-dose epoprostenol in canine PH; leaves open translation to human or veterinary practice.
Pulmonary hypertension (PH) is a life-threatening complication in dogs with cardiopulmonary disease. Epoprostenol is an intravenous pulmonary vasodilator used to treat PH in humans; however, its efficacy in dogs remains unknown. We investigated the cardiovascular effects of epoprostenol and several cardiac agents for acute heart failure in canine models of chronic PH. Six dogs with chronic PH were anesthetized and underwent right heart catheterization and echocardiography before and after infusion of epoprostenol, dobutamine, dopamine and pimobendane. (The drug administration order was the same for all dogs). High-dose epoprostenol (15-20 ng/kg/min) tended to decrease pulmonary arterial pressure (PAP) while significantly decreasing pulmonary and systemic vascular resistance and increasing left and right ventricular (LV and RV, respectively) function. Pimobendan significantly increased LV and RV functions without increasing PAP. Conversely, dobutamine and dopamine significantly increased LV and RV function as well as PAP. This study revealed the efficacy of epoprostenol in treating canine PH through its pulmonary and systemic vasodilating effects. Although catecholamines improve LV and RV function, they might worsen PH pathophysiology, and careful monitoring may be necessary when using these drugs. Pimobendan improved LV and RV function without increasing PAP; however, a stronger vasodilating effect was observed with epoprostenol.
Yuchi et al. (2023) studied Chronic pulmonary hypertension (n=6). Epoprostenol, dobutamine, dopamine, and pimobendan vs. Baseline (before infusion) was evaluated on Cardiovascular effects (pulmonary arterial pressure, vascular resistance, ventricular function). High-dose epoprostenol (15-20 ng/kg/min) significantly decreased pulmonary and systemic vascular resistance and increased ventricular function in dogs with chronic pulmonary hypertension.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: